Email updates

Keep up to date with the latest news and content from BMC Research Notes and BioMed Central.

Open Access Highly Accessed Short Report

Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children

Arthorn Riewpaiboon1*, Issarang Nuchprayoon2, Kitti Torcharus3, Kaemthong Indaratna4, Montarat Thavorncharoensap1 and Bang-on Ubol5

Author Affiliations

1 Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand

2 Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

3 Department of Pediatrics, Phramongkutklao College of Medicine, Bangkok, Thailand

4 Faculty of Economics, Chulalongkorn University, Bangkok, Thailand

5 Department of Pediatrics, Saraburi Hospital, Saraburi, Thailand

For all author emails, please log on.

BMC Research Notes 2010, 3:29  doi:10.1186/1756-0500-3-29

Published: 30 January 2010

Abstract

Background

Hemoglobin E beta-thalassemia (β-thalassemia/Hb E) has a variable severity, and the cost of treatment has not been well studied. The aim of this study was to analyze the societal cost of caring for children with β-thalassemias in Thailand. The study was designed as a prevalence-based cost-of-illness analysis in a societal perspective. Medical records from three public hospitals of children aged 2-18 years with β-thalassemia/Hb E and homozygous β-thalassemia were reviewed for direct medical cost determination. For direct non-medical cost and indirect cost, a family member was interviewed.

Findings

It was found that 201 patients with β-thalassemia/Hb E (91%) and homozygous β-thalassemia (9%) were recruited for this study. Ninety-two (46%) were severe thalassemia and 109 (54%) were mild to moderate severity. The annual average cost of treatment was US$950; 59% was direct medical cost, 17% direct non-medical cost, and 24% indirect cost. The costs were differentiated by some potential predictors. Significant predictor variables were: hospital, health insurance scheme, blood transfusion pattern, and iron chelation drug use.

Conclusions

The average annual cost per patient was calculated, and the cost model was estimated. These would be applied for national planning, economic evaluation of treatment and prevention interventions, and budget impact analysis.